Search Results
Your search for Christopher J. Sweeney, MBBS matches 20 pages
Showing 1 - 20Localized Prostate Cancer: Association of PSA Nadir Within 6 Months of Radiotherapy With Outcomes
In a study reported in the Journal of Clinical Oncology, Kwak et al found that prostate-specific antigen (PSA) levels ≥ 0.1 ng/mL within 6 months after completion of radiotherapy were prognostic for poorer outcomes in patients with localized prostate cancer who did or did not also receive...
Expert Point of View: Christopher J. Sweeney, MBBS
Invited discussant of the PSMAfore trial, Christopher J. Sweeney, MBBS, Director of the South Australian Immunogenics Cancer Institute, University of Adelaide, Australia, congratulated the authors for a well-powered, controlled phase III trial. “The study showed clear documentation of...
Pertuzumab/Trastuzumab for Nonindicated HER2-Altered Advanced Solid Tumors: MyPathway Update
In an updated analysis of a cohort in the phase IIa MyPathway study published in the Journal of Clinical Oncology, Christopher J. Sweeney, MBBS, and colleagues described outcomes with the combination of pertuzumab and trastuzumab in nonindicated HER2-altered advanced solid tumors. As stated by the ...
Primary Overall Survival Analysis of the ENZAMET Trial in Metastatic Hormone-Sensitive Prostate Cancer
As reported in The Lancet Oncology by Christopher J. Sweeney, MBBS, and colleagues, the primary overall survival analysis of the phase III ENZAMET trial showed a significant benefit with enzalutamide plus testosterone suppression vs standard nonsteroidal antiandrogen treatment plus testosterone...
Event-Free Survival as a Surrogate for Overall Survival in Patients With Localized Prostate Cancer Treated With Radiotherapy
In a study reported in the Journal of Clinical Oncology, Xie et al found that event-free survival including prostate-specific antigen biochemical failure as an event is not an adequate surrogate for overall survival in men receiving radiotherapy as primary therapy for localized prostate cancer....
IMbassador250 Trial: No Survival Benefit With Atezolizumab and Enzalutamide in Metastatic Prostate Cancer
The addition of the checkpoint inhibitor atezolizumab to enzalutamide failed to improve overall survival compared with enzalutamide alone in men with metastatic castration-resistant prostate cancer in the phase III IMbassador250 trial, according to results presented at the 2020 American Association ...
ENZAMET Trial Shows Enzalutamide Improves Overall Survival in Hormone-Sensitive Metastatic Prostate Cancer
Agents that improve survival in metastatic castration-resistant prostate cancer when added to background androgen-deprivation therapy (ADT) are showing success in treating metastatic prostate cancer earlier while it is still hormone-sensitive. These agents include docetaxel (chemotherapy) and...
Long-Term Survival Outcomes With Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
Analysis of long-term survival outcomes in the phase III CHAARTED trial showed a survival advantage with the addition of docetaxel to androgen-deprivation therapy (ADT) in patients with hormone-sensitive metastatic prostate cancer, although no advantage was observed among patients with low-volume...
PSA at 7 Months and Prognosis in Metastatic Hormone-Sensitive Prostate Cancer Treated With ADT With or Without Chemotherapy
In a study reported in the Journal of Clinical Oncology, Harshman et al found that a prostate-specific antigen (PSA) level ≤ 0.2 ng/mL at 7 months after the start of androgen-deprivation therapy (ADT) was significantly associated with longer overall survival in metastatic...
Metastasis-Free Survival as Surrogate for Overall Survival in Localized Prostate Cancer
In a meta-analysis reported in the Journal of Clinical Oncology, Xie et al found that metastasis-free survival was a strong surrogate for overall survival in patients with localized prostate cancer, potentially providing a metric that could accelerate assessment of new adjuvant therapy approaches. ...
Deep Androgen Suppression Plus Abiraterone and Prednisone: Effective Strategy for Hormone-Naive Prostate Cancer
ANTAGONISM OF THE ANDROGEN AXIS remains a cornerstone of systemic therapy for high-risk localized and metastatic prostate cancer, reflecting the central role of androgen-dependent biologic mechanisms in hormone-naive disease. Despite the use of standard androgen-deprivation therapy, men with...
Christopher J. Sweeney, MBBS, on Prostate Cancer: CHAARTED Trial Follow-up
Christopher J. Sweeney, MBBS, of the Dana-Farber Cancer Institute, discusses how long-term study results showed no survival benefit in men with ogliometastatic prostate cancer. (Abstract 720PD)
Christopher J. Sweeney, MBBS, on Localized Prostate Cancer: Metastasis-Free Survival as a Surrogate for Overall Survival
Christopher J. Sweeney, MBBS, of the Dana-Farber Cancer Institute, discusses how this early clinical endpoint will accelerate the development of new therapies for localized intermediate and high-risk prostate cancer. (Abstract 717O)
Christopher J. Sweeney, MBBS: Testicular Cancer Update
Christopher J. Sweeney, MBBS, of the Dana-Farber Cancer Institute, reviews important presentations on testicular cancer, including dose intensification for first-line therapy of metastatic disease, and what physicians need to know about the molecular genetics of testicular cancer.
My First of Many ASCO Meetings
In June, I attended my first ASCO Annual Meeting. Although I have been practicing and teaching urology for 35 years with a specific interest in genitourinary oncology and I have attended dozens of national meetings, the ASCO Annual Meetings were not on my radar. Focus on the Patient The...
‘Unprecedented’ Survival Benefit in Prostate Cancer With Addition of Docetaxel to Hormone Therapy
Adding docetaxel to standard androgen ablation therapy (ie, testosterone suppression) extended survival by more than 1 year in men with newly diagnosed metastatic hormone-sensitive prostate cancer in the phase III E3805 trial, funded by the National Institutes of Health. As reported at the ASCO...
Expert Point of View: Christopher J. Sweeney, MBBS
These latest results of STAMPEDE lend further support to the early use of chemotherapy in men with advanced prostate cancer. They confirm the CHAARTED trial results reported last year by Christopher J. Sweeney, MBBS, which were practice-changing. Men with newly diagnosed metastatic...
CHAARTED and GETUG-15 Studies
At the 2014 ASCO Annual Meeting, the phase III E3805 (CHAARTED) trial presented at the Plenary Session showed that the addition of docetaxel to standard hormone therapy extended survival by more than 1 year in men with newly diagnosed, hormone-sensitive prostate cancer.1 The survival benefit of...
Adding Docetaxel to Androgen-Deprivation Therapy Prolongs Overall Survival in Metastatic Prostate Cancer
In a phase III trial (E3805) reported in The New England Journal of Medicine, Christopher J. Sweeney, MBBS, of Dana-Farber Cancer Institute, Boston, and colleagues found that chemohormonal therapy with docetaxel plus androgen-deprivation therapy produced a significant 13.6-month increase in median...
ASCO 2014: Adding Docetaxel to Androgen-Deprivation Therapy Significantly Improves Survival in Hormone-Sensitive Prostate Cancer
The addition of docetaxel to androgen-deprivation therapy extended survival for men with newly diagnosed hormone-sensitive prostate cancer by more than 13 months in the National Cancer Institute–led phase III E3805 study. The survival benefit was even greater for men with high-volume disease. ...
